ImpactIntel Research’s Post

PanMediso Spotlight｜Novel Chelator L804 Reduces Toxicity in PSMA Radiopharmaceutical Therapy At the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI) meeting, a study led by Dr. Carolyn Anderson demonstrated that a new chelator (L804) significantly reduces off-target toxicity in PSMA radiotherapy. Compared to standard chelators (DOTA, DFO), L804 improves the binding of radioactive metals to PSMA-targeted antibodies, enhancing safety and efficacy. Tested in mice with prostate cancer with radiolabeled antibodies (177Lu-L804-IAB2MA and 89Zr-L804-IAB2MA), L804 showed lower radioactive accumulation and toxicity, offering better patient safety and treatment outcomes. PanMediso Holdings is committed to building a global ecosystem of industry, academia, research, diagnosis & treatment for nuclear medicine and establishing world-class preparation & production centers of medical isotope to realize the GMP-grade production and global supply of new-type isotopes, particularly Ac-225 and Ge-68, thereby bringing new power to the development of human health. #radiopharmaceuticals #prostatecancer #L804 #DOTA #DFO #177Lu

Source: Journal of nuclear medicine : official publication, Society of Nuclear Medicine DPI-4452 is a potential theranostic ligand for carbonic anhydrase IX (CAIX), a protein highly expressed in certain tumor types. The ligand was evaluated in vitro and in vivo using radiolabeled versions and showed selective binding to CAIX with high affinity. In animal models, the ligand localized to tumors and demonstrated tumor growth inhibition. This suggests that DPI-4452 could be used for selecting and treating patients with CAIX-expressing tumors.

PanMediso Spotlight｜Applications and Advantages of 68Ga in PET Imaging 68Ga (Gallium-68) is a widely used radionuclide in the field of nuclear medicine, particularly suited for positron emission tomography (PET) imaging. It does not require on-site cyclotron preparation and has a half-life of 68 minutes, with a positron decay rate of 89%. 68Ga-labeled radiopharmaceuticals are extensively applied in tumor imaging, including prostate cancer, neuroendocrine tumors (NENs), and for the diagnosis and staging of malignant tumors. Additionally, they are used in imaging for myocardial perfusion, lung perfusion, as well as inflammation and infection. We PanMediso Holdings is committed to building a global ecosystem of industry, academia, research, diagnosis & treatment for nuclear medicine and establishing world-class preparation & production centers of medical isotope to realize the GMP-grade production and global supply of new-type isotopes, particularly Ac-225 and Ge-68, thereby bringing new power to the development of human health. #Radiopharmaceutical #68Ga #PET #prostatecancer #NENs

How are you today? Tell us what you want to hear from us. In 2011, me and Prof. Dr. Frank Rösch, founded the very first Theranostics World Congress (TWC) in the field of nuclear medicine covering the topics Gallium-68 and Peptide Receptor Radionuclide Therapy - THERANOSTICS – on the Way to Personalized Medicine.  ince then, the TWC has developed as the most important forum for mutual exchange and a true bench to bedside view on scientific and clinical developments. With this 360° perspective on Theranostics and Radiomolecular Precision Oncology, the TWC is truly a platform for all players in this exciting field.  And this worldwide! From Europe to India over America to Australia and Asia, the TWC was held in several venues around the world. Over the years, the field of Theranostics has been growing outstandingly with an exponential increase in publications, new clinical indications, promising novel radioisotopes, and new treatment concepts.  Even more than 10 years after the first TWC took place, the exciting fields of Theranostics and Radiomolecular Precision Oncology are still at its beginnings. We want to take a 360° view on the wide field of Theranostics in Radiomolecular Precision Oncology.

Transforming Cancer Care: The Power of Nuclear Therapeutics Over Traditional X-Rays! Nuclear therapeutics represents a groundbreaking advancement in cancer therapy. It utilizes radioactive drugs that specifically target and eliminate cancer cells. This innovative approach is increasingly favored over traditional X-rays and other radiation imaging technologies. The market demand for nuclear therapeutics is expected to rise significantly, driven by extensive research and development activities within the commercial sector. Ambulatory surgery centers (ASCs) are progressively adopting nuclear therapeutics due to its numerous benefits, including improved patient outcomes, substantial cost savings (45%–60% less expensive than hospital treatments), reduced wait times, and personalized care. #nucleartherapeutics #cancertherapy #beneficial

New paper published today by our founder and CSO at KayoThera, Mark Esposito, Ph.D Esposito, along with Yibin Kang and John Amory. In this paper, they explore the history of Vitamin A in human health and how we can turn off retinoid nuclear receptor signaling could help to combat #diabetes, #obesity, and #cancer. At KayoThera, we've been building a pipeline of medicines to inhibit retinoid signaling, and are developing programs nearing the clinic in cancer and type 2 diabetes.

Which mechanisms regulate #immunogenic #cancer cell death via the high mobility group box 1 and 2 (#HMGB1 and #HMGB2) proteins? With help from a LUNA-FL Dual #Fluorescence #CellCounter, scientists showed the key role of the nuclear exporter #XPO1 in this process. https://ow.ly/64If50TJ6l2 #cellcount #cellcounting #oncology #oxaliplatin #calreticulin #ferroptosis

Scientists from Yale University have developed a stealthy cancer therapy: antinuclear antibody–drug conjugates (ANADCs)! ANA nuclear penetration induces nuclear flux by the lysosomal protease cathepsin B and leverage this mechanism to design an ANADC with cathepsin B-labile drug linker. The ANADC targets nucleic acid exhaust from necrotic tumors and crosses membrane barriers through nucleoside salvage as a DNA-seeking and tumor agnostic “antinuclear missile” cancer therapy. Read the full paper at ACS Publications: https://lnkd.in/e24XDMRG Study by Fei Cao et al. #Biointron #Antibodies #DrugDevelopment #DrugDiscovery #Cancer #Oncology #Innovation #ADC #Therapy #Healthcare #AntibodyEngineering

🚀 Exciting Advancement in Neuroendocrine Tumor Treatment! 🚀 Preclinical radiopharmaceutical showdowns will become more common in this developing landscape! This study, published in The Journal of Nuclear Medicine - JNM highlights the efficacy of [67Cu]Cu-EB-TATE theranostic in treating somatostatin receptor subtype-2 (SSTR2)-positive neuroendocrine tumors (NETs). 🔬 Key Highlights 🔬: ☢️Innovative Therapy: [67Cu]Cu-EB-TATE demonstrates superior decay properties and imaging capabilities than the traditionally used [177Lu]Lu-EB-TATE. ☢️Enhanced Effectiveness: In preclinical trials, [67Cu]Cu-EB-TATE showed a 60% success rate in eliminating small tumors (<50 mm³) within 15 days, outperforming [177Lu]Lu-EB-TATE's 20%. ☢️Improved Patient Outcomes: The treatment extended mean survival significantly, with treated groups showing survival times of over 90 days, compared to 26-53 days for control groups. This research, led by Fabrice Ngoh Njotu and team, positions [67Cu]Cu-EB-TATE as a promising candidate for clinical development, #NuclearMedicine #NeuroendocrineTumors #Theranostics #MedicalResearch #HealthcareInnovation #CancerTreatment

💊 Radiotherapy is challenged globally with a worryingly inadequate supply chain capacity. We are seeing this during phased trials, with lack of availability hampering the prospect of these drugs being marketed as approved #oncology treatments that have the potential to save the lives of millions of #cancer patients. entX Limited’s IsoMedica business exists for this very reason, to develop a unique supply chain for the production of emerging radioisotopes, Lutetium-177 and Lead-212, being used in #nuclear medicines. What’s more is that we will be repurposing low level waste from the resources sector and underutilised materials bearing the precursor isotopes and we plan to do this at a scale that has a global impact. #Circular economies saving lives. #entX #IsoMedica #Radiopharmaceuticals #NuclearMedicine Massey de los Reyes Bryn Jones Julian F. Kelly Bristol Myers Squibb